Neil A Bhowmick, Ph.D., Professor of
Medicine at Cedars-Sinai Medical Center. He is the Director of the Cancer
Biology Program at Cedars-Sinai Cancer (ranked 7th by US News & World
Report), serves on the editorial boards of four scientific journals, is a charter
member of an NIH grant study section, and serves as the Chief Scientific Officer
for Armida Labs, Inc. Bhowmick brings more than 20 years of broad biochemistry
and cancer biology expertise; he has published in peer-reviewed journals on topics
ranging from pre-clinical cancer studies to translational research, including
regulatory approvals and clinical trials. Bhowmick is credited for
defining the role of fibroblasts in cancer initiation as an alternative
mechanism to the familiar two-hit hypothesis where one epigenetic alteration is
in the fibroblasts, complementing a mutation in the epithelia. He has gone on
to discover the role of fibroblasts in cancer therapy resistance and has used
these findings to extend the time of cancer remission in multiple cancer types
in preclinical and clinical studies. Bhowmick was also among the first to show
the tumor-suppressive role of fibroblasts and their role in collagen matrix
assembly in supporting the strength of healed skin wounds. He was a founder and
CEO of Enviro Therapeutics Inc., recently acquired and taken public. He trained
at Vanderbilt University.
Neil A Bhowmick, Ph.D., Professor of
Medicine at Cedars-Sinai Medical Center. He is the Director of the Cancer
Biology Program at Cedars-Sinai Cancer (ranked 7th by US News & World
Report), serves on the editorial boards of four scientific journals, is a charter
member of an NIH grant study section, and serves as the Chief Scientific Officer
for Armida Labs, Inc. Bhowmick brings more than 20 years of broad biochemistry
and cancer biology expertise; he has published in peer-reviewed journals on topics
ranging from pre-clinical cancer studies to translational research, including
regulatory approvals and clinical trials. Bhowmick is credited for
defining the role of fibroblasts in cancer initiation as an alternative
mechanism to the familiar two-hit hypothesis where one epigenetic alteration is
in the fibroblasts, complementing a mutation in the epithelia. He has gone on
to discover the role of fibroblasts in cancer therapy resistance and has used
these findings to extend the time of cancer remission in multiple cancer types
in preclinical and clinical studies. Bhowmick was also among the first to show
the tumor-suppressive role of fibroblasts and their role in collagen matrix
assembly in supporting the strength of healed skin wounds. He was a founder and
CEO of Enviro Therapeutics Inc., recently acquired and taken public. He trained
at Vanderbilt University.